Our report showed that this pharmaceutical could reduce blood system infection related costs for Medicare by 75% and eliminate the need for an expensive drug used to dissolve blood closts. The technology could also create more revenue for dialysis treatment centers as patients would be admitted less times to the hospital and more to the dialysis centers.
Primary Impact suggested not pursuing this technology until Medicare approves reimbursement and understands the resulting cost savings to Medicare of reduced hospital treatments for blood system infections.
Market Intelligence indicates timing issue
With the delays of Medicare's approval process and the time required to penetrate the market, the business decided that a "pharmaceutical" or "medical device business" was better positioned to acquire and execute this technology. Click to learn more about Primary Impact's pharmaceutical industry practice.
